Literature DB >> 27097945

Anticancer drugs with chemotherapeutic interactions with thymoquinone in osteosarcoma cells.

H Sarman1, R Bayram, S B Benek.   

Abstract

OBJECTIVE: Osteosarcoma (OS) is the most common primary malignant tumor of the bone. Treatment options include surgery, chemotherapy, and radiotherapy. Following surgery, multi-agent chemotherapy drugs are effective but are associated with significant side effects and toxicity. Thymoquinone (TMQ) is a pharmacological component of black cumin that has multiple anti-tumorigenic effects. The goal of this study was to determine the effect of TMQ in combination with chemotherapy drugs on the growth inhibition of osteosarcoma and the potential clinical utility of TMQ in the treatment of OS.
MATERIALS AND METHODS: We evaluated the effects on the MG63 OS cell line when TMQ, 5-fluorouracil, and oxaliplatin combinations were applied that MG63 OS cell line viability was measured with the cell proliferation and apoptosis assay according to dose and time-dependent effects.
RESULTS: Application of 10 µM TMQ combined with 5FU and OXA at a low concentration of 1 µM that was discovered an ineffective dose of the used drugs as anticancer decreased cell viability and increased apoptosis in cells at a significant rate at 48 and 72 h.
CONCLUSIONS: TMQ has potential benefits in preventing the onset and progression of chemotherapy drug-induced toxicity and side effects, and may reduce resistance to chemotherapy drugs. We consider that TMQ may be a potential therapeutic drug for OS and/or other cancers.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27097945

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  7 in total

1.  Formulation, Cellular Uptake and Cytotoxicity of Thymoquinone-Loaded PLGA Nanoparticles in Malignant Melanoma Cancer Cells.

Authors:  Wisam Nabeel Ibrahim; Luqman Muizzuddin Bin Mohd Rosli; Abd Almonem Doolaanea
Journal:  Int J Nanomedicine       Date:  2020-10-20

Review 2.  Thymoquinone as a Potential Adjuvant Therapy for Cancer Treatment: Evidence from Preclinical Studies.

Authors:  A G M Mostofa; Md Kamal Hossain; Debasish Basak; Muhammad Shahdaat Bin Sayeed
Journal:  Front Pharmacol       Date:  2017-06-12       Impact factor: 5.810

3.  Novel thymoquinone lipidic core nanocapsules with anisamide-polymethacrylate shell for colon cancer cells overexpressing sigma receptors.

Authors:  Lydia Ramzy; Abdelkader A Metwally; Maha Nasr; Gehanne A S Awad
Journal:  Sci Rep       Date:  2020-07-03       Impact factor: 4.379

4.  Investigation of cellular effects of thymoquinone on glioma cell.

Authors:  Eray Metin Guler; Behice Hande Sisman; Abdurrahim Kocyigit; Mustafa Aziz Hatiboglu
Journal:  Toxicol Rep       Date:  2021-01-04

Review 5.  Thymoquinone, as a Novel Therapeutic Candidate of Cancers.

Authors:  Belal Almajali; Hamid Ali Nagi Al-Jamal; Wan Rohani Wan Taib; Imilia Ismail; Muhammad Farid Johan; Abd Almonem Doolaanea; Wisam Nabeel Ibrahim
Journal:  Pharmaceuticals (Basel)       Date:  2021-04-16

Review 6.  Potential anticancer properties and mechanisms of thymoquinone in osteosarcoma and bone metastasis.

Authors:  Mina Homayoonfal; Zatollah Asemi; Bahman Yousefi
Journal:  Cell Mol Biol Lett       Date:  2022-03-02       Impact factor: 5.787

7.  A correlation analysis between tumor imaging changes and p-AKT and HSP70 expression in tumor cells after osteosarcoma chemotherapy.

Authors:  Feng Ji; Ran Lv; Ting Zhao
Journal:  Oncol Lett       Date:  2017-09-20       Impact factor: 2.967

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.